<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01579097</url>
  </required_header>
  <id_info>
    <org_study_id>CSPIVTCHN001</org_study_id>
    <nct_id>NCT01579097</nct_id>
  </id_info>
  <brief_title>Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-chamber Parenteral Nutrition Formulation</brief_title>
  <official_title>A Randomized, Comparative Phase 3 Trial to Assess the Safety and Efficacy of Triple-Chamber Parenteral Nutrition Formulation (Oliclinomel N4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baxter Healthcare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the safety and efficacy of Oliclinomel N4 compared
      to compounded ternary parenteral nutrition (PN) admixtures for the delivery of PN in
      hospitalized adults for whom oral or enteral nutrition is not possible, insufficient, or
      contraindicated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Prealbumin</measure>
    <time_frame>Serum Prealbumin at Day 5</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">458</enrollment>
  <condition>Nutrition Support</condition>
  <arm_group>
    <arm_group_label>compounded ternary parenteral nutrition</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>compounded ternary Parenteral Nutrition admixture</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oliclinomel N4 formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oliclinomel N4 is a ready-to-use PN product presented as a triple chamber bag</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oliclinomel N4</intervention_name>
    <description>Oliclinomel is a PN product which provides the macronutrients (e.g., dextrose, amino acids, and lipids) for patients when oral or enteral nutrition is not possible, insufficient, or contraindicated</description>
    <arm_group_label>Oliclinomel N4 formulation</arm_group_label>
    <other_name>Oliclinomel N4-550</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Compounded ternary parenteral nutrition admixtures</intervention_name>
    <description>Study treatment will be administered for a minimum of 5 days up to a maximum of 14 days</description>
    <arm_group_label>compounded ternary parenteral nutrition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Inpatient but hospitalized &lt; 14 days prior to enrollment

          -  Requires PN because oral or enteral nutrition is not possible, insufficient, or
             contraindicated

          -  Has capability to complete at least 5 days of study treatment (i.e., PN)

          -  Has a useable peripheral vein for delivery of intravenous (IV) PN

        Exclusion Criteria:

          -  Has a life expectancy of &lt; 6 days from initiation of study treatment, in the opinion
             of the Investigator

          -  Known hypersensitivity to the components of either of the investigational study
             treatments

          -  Use of prohibited medications (e.g. glucocorticosteroids or antitumor chemotherapeutic
             agents) within 30 days prior to enrollment

          -  Known serious clinically significant condition that would preclude participation in
             the study

          -  Known chronic active hepatitis, elevated liver function tests

          -  Known history of human immunodeficiency virus infection

          -  Known severe dyslipidemia, severe hyperglycemia,clinically significant abnormalities
             of plasma electrolytes

          -  Known pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baxter Investigative Site</last_name>
    <role>Study Director</role>
    <affiliation>Shanghai, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baxter Investigative Site</last_name>
    <role>Study Director</role>
    <affiliation>Shantou, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baxter Investigative Site</last_name>
    <role>Study Director</role>
    <affiliation>Haikou, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baxter Investigative Site</last_name>
    <role>Study Director</role>
    <affiliation>Jiangsu Province, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baxter Investigative Site</last_name>
    <role>Study Director</role>
    <affiliation>Beijing, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baxter Investigative Site</last_name>
    <role>Study Director</role>
    <affiliation>Changsha, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baxter Investigative Site</last_name>
    <role>Study Director</role>
    <affiliation>Hangzhou, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baxter Investigative Site</last_name>
    <role>Study Director</role>
    <affiliation>Nanning, China</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Baxter Investigative Site</last_name>
    <role>Study Director</role>
    <affiliation>Shang dong Province, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai No. 6 Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>April 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2012</study_first_posted>
  <last_update_submitted>January 31, 2013</last_update_submitted>
  <last_update_submitted_qc>January 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>(PN) Parenteral nutrition</keyword>
  <keyword>oral/enteral not possible</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

